BioSpace News Archive

Teneobio, Inc. and its affiliate TeneoFour, Inc. announced a Nature Metabolism publication of a proof of concept study by the Chini Laboratory describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.

Telo Genomics Corp. is pleased to announce the positive results of its smoldering multiple myeloma proof of concept study, recently published within the proceedings of the American Society of Hematology annual meeting 2020.

Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020

Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting ® 2020 Data support potential utility for treatment of NASH Analysis of results from the Phase 1b study of PXL065 (deuterium-stabilized R-pioglitazone) predicts efficacy at 15 mg once-daily is equivalent to 45 mg Actos ®* , with little to no PPARg-related side effects, such as weight gain

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences: Craig-Hallum Alpha Select Virtual Conference Tuesday, Nov. 17, 2020 (one-on-one meetings only) Benchmark

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

BIOREM Inc. announced a number of new orders totalling $10.8 million.

Today, the U.S. Food and Drug Administration approved Stelfonta (tigilanol tiglate injection) to treat dogs with non-metastatic, skin-based (cutaneous) mast cell tumors (MCTs).

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Third Quarter 2020 financial results and to provide a business update

Tauriga Sciences, Inc. announced that it has extended its relationship with Chinese E-Commerce & Retail giant, Alibaba Group, for a period of an additional 12 months.